SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

9 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Selected Information by Business Segment

Selected information by reportable segment is presented below:

	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2022		January 1, 2022		December 31, 2022		January 1, 2022
Net revenues
Plasma	$	136,574	$	96,692	$	368,504	$	250,499
Blood Center	76,827		74,527		219,052		221,522
Hospital	93,889		82,100		275,635		235,609
Net revenues by business unit	307,290		253,319		863,191		707,630
Service (1)	5,372		5,436		15,918		15,655
Effect of exchange rates	(7,361)		1,014		(14,865)		4,909
Net revenues	$	305,301	$	259,769	$	864,244	$	728,194
(1) Reflects revenue for service, maintenance and parts

	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2022		January 1, 2022		December 31, 2022		January 1, 2022
Segment operating income
Plasma	$	76,365	$	51,405	$	203,098	$	128,964
Blood Center	35,005		34,561		102,710		103,043
Hospital	37,557		35,072		110,762		97,898
Segment operating income	148,927		121,038		416,570		329,905
Corporate expenses (1)	(93,502)		(68,013)		(261,855)		(204,930)
Effect of exchange rates	3,581		5,807		9,775		15,553
Integration and transaction costs	(287)		(1,860)		425		(19,218)
Deal amortization	(8,078)		(12,151)		(24,666)		(35,930)
Restructuring and restructuring related costs	(4,123)		(5,682)		(10,795)		(20,250)
Impairment of assets and PCS2 related charges	1		(897)		268		(4,790)
MDR and IVDR costs	(2,483)		(2,453)		(8,175)		(7,171)
Litigation-related charges	(757)		(138)		(1,151)		(1,221)
Gains on divestiture	—		—		382		9,603
Operating income	$	43,279	$	35,651	$	120,778	$	61,551
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Schedule of Revenues by Product Line and Geographic Regions

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:

	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2022		January 1, 2022		December 31, 2022		January 1, 2022
Plasma products and services	$	153,899	$	116,347	$	415,412	$	308,931
Blood Center products and services	58,273		59,440		173,086		177,118
Hospital products and services	93,129		83,982		275,746		242,145
Net revenues	$	305,301	$	259,769	$	864,244	$	728,194

Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:

	Three Months Ended				Nine Months Ended
(In thousands)	December 31, 2022		January 1, 2022		December 31, 2022		January 1, 2022
United States	$	224,104	$	167,270	$	617,824	$	460,404
Japan	15,552		19,916		44,559		55,949
Europe	39,105		41,540		121,412		126,055
Asia	25,454		30,434		77,739		83,157
Other	1,086		609		2,710		2,629
Net revenues	$	305,301	$	259,769	$	864,244	$	728,194